Abstract: Lonafarnib (SCH66336) is an orally active, nonpeptidic farnesyltransferase inhibitor originally discovered and developed as an investigational antineoplastic agent for solid tumors and hematological malignancies. While its clinical development in oncology was largely discontinued due to a lack of monotherapy efficacy—primarily attributed to the alternative geranylgeranylation of target Ras proteins—lonafarnib has found significant clinical utility in other therapeutic domains. In November 2020, it received its first FDA approval for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies. Furthermore, it is under advanced clinical investigation for the treatment of Hepatitis D Virus (HDV) infection. This review explores the pharmacological activity, molecular mechanisms, structure-activity relationships, and current limitations of lonafarnib, with a specific focus on its historical context in oncology and future perspectives in precision cancer therapy and combination regimens.
1. Introduction
Lonafarnib, also known by its developmental codes SCH66336 and trade name Zokinvy™, is an orally active farnesyltransferase (FTase) inhibitor [1]. The drug was originally discovered by Merck & Co. as an investigational targeted therapy in oncology, aimed at treating various solid tumors, myelodysplastic syndromes (MDS), and leukemias [1]. Despite early promise, the clinical development of lonafarnib for oncology indications was largely discontinued due to a lack of sufficient efficacy in human trials [1].
Following its discontinuation in oncology, lonafarnib was repurposed through a licensing agreement with Eiger BioPharmaceuticals [1]. On November 20, 2020, lonafarnib achieved a major milestone by receiving its first approval in the USA to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) and for the treatment of processing-deficient progeroid laminopathies in patients 12 months of age and older [1]. Beyond progeria, lonafarnib is currently undergoing extensive clinical development in multiple countries for the treatment of chronic Hepatitis D Virus (HDV) infections [1].
2. Pharmacological Activity
In the context of oncology, lonafarnib has been evaluated in multiple Phase I and Phase II clinical trials for advanced solid tumors, acute leukemias, chronic myelogenous leukemia (CML), and MDS [3]. In a Phase II study involving patients with MDS and chronic myelomonocytic leukemia (CMML), lonafarnib demonstrated modest pharmacological activity, with hematologic improvement noted in a small subset of patients (6 MDS and 10 CMML patients) [4]. However, significant toxicity profiles led to early treatment withdrawals, prompting recommendations for intermittent dosing schedules in future trials [4]. Preclinical studies have also shown that lonafarnib can synergize with taxanes (such as paclitaxel) in vitro and enhance their antitumor activity in vivo, effectively inhibiting the proliferation of murine ovarian cancer models [2].
In progeria, lonafarnib exhibits profound pharmacological benefits. Clinical trials have demonstrated that lonafarnib monotherapy increases the average lifespan of patients with HGPS by an average of 2.5 years over an 11-year follow-up compared to untreated cohorts [1]. It also improves the rate of weight gain, decreases arterial pulse wave velocity (vascular stiffness), and improves bone structure and audiological status [1] [6].
In virology, lonafarnib has shown a strong antiviral dose-response against HDV. Phase II proof-of-concept studies (such as the LOWR-HDV trials) demonstrated that lonafarnib significantly reduces HDV RNA levels [1]. To optimize its pharmacological profile and minimize gastrointestinal side effects, lonafarnib is often co-administered with ritonavir, a CYP3A4 inhibitor, which allows for lower dosing while achieving higher post-absorption systemic concentrations [1] [9] [11].
3. Molecular Mechanism of Action
Lonafarnib is a nonpeptidic, CAAX-competitive, selective inhibitor of the enzyme farnesyltransferase (FTase) [1]. FTase is responsible for attaching a 15-carbon farnesyl isoprenoid lipid to the cysteine residue of proteins containing a C-terminal CAAX motif (where C is cysteine, A is an aliphatic amino acid, and X is the terminal amino acid) [6] [7].
In oncology, the primary rationale for using FTase inhibitors like lonafarnib was to target the Ras family of small GTPases (such as H-Ras, K-Ras, and N-Ras), which are mutated and constitutively activated in approximately 20% of human cancers [3]. Ras proteins require farnesylation to anchor to the plasma membrane, a critical step for the activation of downstream oncogenic signaling cascades (e.g., MAPK and PI3K pathways) [3] [4]. By inhibiting FTase, lonafarnib prevents the membrane localization of Ras, thereby disrupting its oncogenic function [6].
In HGPS, the disease is caused by a mutation in the LMNA gene, leading to the production of a permanently farnesylated, mutant prelamin A protein called progerin [1] [6]. Progerin accumulates in the inner nuclear membrane, severely disrupting nuclear architecture and causing premature cellular senescence. Lonafarnib blocks the farnesylation of progerin, preventing its accumulation and restoring normal nuclear structure [1].
In HDV infection, the virus relies on host FTase to prenylate the large hepatitis D antigen (LHDAg). This farnesylation is essential for the interaction between LHDAg and the Hepatitis B surface antigen (HBsAg), a step required for viral particle assembly and secretion. Lonafarnib prevents this envelopment process, thereby halting viral replication [7] [11].
4. Structure-Activity Relationship (SAR)
Chemically, lonafarnib is designated as 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5Hbenzo[1,2] cyclohepta [2,4-b]pyridin-11-yl]piperidin-1-yl]-2- oxoethyl] piperidine-1-carboxamide [1]. It belongs to a diverse structural class encompassing amides, piperidines, pyridines, and halogenated hydrocarbons [1].
Unlike early FTase inhibitors that were designed as peptidomimetics mimicking the CAAX tetrapeptide box, lonafarnib is a non-peptidomimetic, enzyme-specific inhibitor identified through high-throughput screening [3]. Its structure allows it to act as a CAAX-competitive inhibitor, meaning it competitively blocks the CAAX motif binding site on the FTase enzyme, thereby preventing the enzyme from interacting with its natural protein substrates [1] [2].
5. Current Limitations
The most significant limitation of lonafarnib in oncology is its lack of clinical efficacy as a monotherapy for most solid tumors and hematological malignancies [1] [3]. This failure is primarily due to a biological escape mechanism: when FTase is inhibited, K-Ras and N-Ras proteins can undergo alternative prenylation (geranylgeranylation) mediated by the enzyme geranylgeranyltransferase type I (GGTase-I) [3] [6]. This alternative lipid modification allows K-Ras and N-Ras to successfully anchor to the cell membrane and retain their oncogenic signaling activity despite FTase inhibition [3].
Additionally, lonafarnib is associated with a notable toxicity profile. The most frequent adverse events include severe gastrointestinal toxicities (vomiting, diarrhea, nausea), decreased appetite, fatigue, and upper respiratory tract infections [1]. Hepatotoxicity, characterized by elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, as well as increased blood pressure, have also been reported [1] [2]. In early MDS trials, these toxicities frequently led to treatment discontinuation [4].
Pharmacokinetically, lonafarnib is heavily metabolized by the CYP3A4 enzyme [1]. Co-administration with strong CYP3A4 inhibitors or inducers significantly alters its area under the curve (AUC) and maximum plasma concentration (Cmax), creating a high potential for drug-drug interactions that require careful clinical management [1].
6. Future Perspectives
Despite its limitations as a monotherapy in broad oncology applications, lonafarnib holds future potential in precision medicine and combination therapies. Because H-Ras (unlike K-Ras and N-Ras) relies exclusively on farnesylation and cannot be alternatively geranylgeranylated, tumors driven specifically by H-Ras mutations (such as certain head and neck squamous cell carcinomas or urothelial cancers) may be highly susceptible to FTase inhibitors [2] [3]. Identifying patients with specific H-Ras mutations could repurpose lonafarnib for targeted oncological use.
To overcome the geranylgeranylation escape mechanism in K-Ras and N-Ras driven tumors, future therapeutic strategies may involve the concomitant use of FTase inhibitors (like lonafarnib) and GGTase-I inhibitors, or the development of dual FTase/GGTase-I inhibitors (such as FGTI-2734 or L-778,123) to achieve synergistic cytotoxic effects [3] [6]. Furthermore, combining lonafarnib with other chemotherapeutic agents, such as taxanes, has shown preclinical synergy and remains an area of interest [2].
In non-oncology indications, the future of lonafarnib involves optimizing combination regimens. For HDV, combining lonafarnib with ritonavir (to boost pharmacokinetics) and pegylated interferon-alpha (PEG-IFN-α) has demonstrated synergistic antiviral efficacy and is the subject of ongoing Phase III trials [1] [9] [11]. In progeria, clinical trials are currently evaluating the combination of lonafarnib with everolimus to further improve patient outcomes [1] [6].
